RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.

ABSTRACT:

Background

Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC. Recent genomic studies implicated the Hippo / Yap signal is over activated in TNBC, manifesting it plays a key role in TNBC carcinogenesis and cancer progression. RBCK1 was firstly identified as an important component for linear ubiquitin assembly complex (LUBAC) and facilitates NFKB signaling in immune response. Further studies showed RBCK1 also facilitated luminal type breast cancer growth and endocrine resistance via trans-activation estrogen receptor alpha.

Methods

RBCK1 and YAP prote

SUBMITTER: Li Z 

PROVIDER: S-EPMC9590148 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature